Market Performance - The Hong Kong stock market closed early due to the New Year holiday, with the Hang Seng Index rising 27.77% for the year, closing at 25,630.54 points [1] - The Technology Index increased by 23.45%, closing at 5,515.98 points, while the National Enterprises Index rose by 22.27%, closing at 8,913.68 points [1] Daily Market Movement - On the last trading day of the year, the market showed light trading activity, with the Hang Seng Index down 0.87%, the Technology Index down 1.12%, and the National Enterprises Index down 0.86% [3] Sector Highlights Film and Entertainment - Film stocks led the market, with major gains from companies like Dama Entertainment (+5.56%), Maoyan Entertainment (+3.12%), and Huayi Brothers (+1.59%) [8] - The 2025 New Year box office reached 5.245 billion yuan, marking an eight-year high, with a 76.35% year-on-year increase in November box office [9] Aviation - Airline stocks surged due to increased travel demand for the New Year holiday, with China Eastern Airlines (+4.92%), China Southern Airlines (+4.30%), and Air China (+3.36%) showing significant gains [10] - Domestic flight ticket bookings exceeded 2.71 million, a 35% year-on-year increase, with average ticket prices rising by 6.7% [11] Cryptocurrency - Cryptocurrency-related stocks saw gains, with HashKey Holdings (+11.33%) and OSL Group (+4.29%) benefiting from favorable policy developments regarding digital currency [12] - The new digital RMB framework will take effect on January 1, 2026, enhancing market expectations for compliant cryptocurrency ecosystems [13] Robotics - Robotics stocks faced pressure, with MicroPort Robotics (-8.72%) and DJI (-4.29%) declining, despite the establishment of a new standardization committee for humanoid robots [14][15] Pharmaceuticals - Pharmaceutical stocks continued to struggle, with companies like Fonda Holdings (-1.96%) and WuXi Biologics (-1.93%) showing declines [17] - The upcoming J.P. Morgan Healthcare Conference is expected to attract over 8,000 participants, including major Chinese pharmaceutical firms [18] Individual Stock Movements - Xuanwu Cloud saw a significant intraday rise of over 13% following news of a strategic investment from Hantang Mingyuan [19] - Boke Vision Cloud experienced a rise of over 9% after its largest shareholder extended the lock-up period for shares [20]

Core Viewpoint - The Hong Kong pharmaceutical market is experiencing a downturn, with the Hong Kong Stock Connect Innovation Drug ETF (159570) declining by 1.14% and over 25% from its previous high, despite a significant trading volume of over 1.44 billion yuan [1][4]. Group 1: Market Performance - The Hong Kong Stock Connect Innovation Drug ETF (159570) has seen a three-day decline, reaching a new low, with a total trading volume exceeding 14.4 billion yuan [1]. - As of December 29, the latest scale of the Hong Kong Stock Connect Innovation Drug ETF (159570) is over 21.9 billion yuan, leading among its peers [1]. - Major stocks within the ETF, such as King’s Bio and Kelun-Bio, have experienced declines, with King’s Bio dropping over 3% [4][5]. Group 2: IPO Activity - On December 30, Insilico Medicine, a generative AI-driven biopharmaceutical company, successfully listed on the Hong Kong Stock Exchange, marking it as the first AI biopharmaceutical company to do so under the main board listing rules [3]. - The IPO raised a total of 2.277 billion Hong Kong dollars, making it the highest fundraising biopharmaceutical IPO in Hong Kong for the year [3]. Group 3: Industry Trends - The upcoming J.P. Morgan Healthcare Conference in January 2026 is expected to attract over 8,000 global participants, featuring more than 500 listed companies and thousands of startups, focusing on "capital + strategy" discussions [6]. - Key trends highlighted for the industry include the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the emergence of new market forces from China [7]. Group 4: Investment Insights - Multinational corporations (MNCs) are willing to pay higher prices for innovative drugs and technology platforms from China, with average total deals from China reaching 2.756 billion USD compared to 1.289 billion USD from overseas [8]. - The pressure from patent expirations, estimated at around 300 billion USD in sales, is driving MNCs to seek high-potential assets in China, particularly in advanced fields like ADCs and cell therapies [9]. - MNCs are shifting their focus from merely acquiring products to obtaining platforms and technologies that can yield new molecules, indicating a strategic evolution in their investment approach [10]. Group 5: Key Investment Areas - Key investment areas include ADCs, GLP-1 for metabolic diseases, bispecific antibodies, and neuroscience, with a focus on companies that can deliver competitive clinical data and innovative platforms [12][13].

Group 1 - The 44th J.P. Morgan Healthcare Conference (JPM) will be held from January 12 to 15, 2026, in San Francisco, attracting over 8,000 global participants and featuring more than 500 listed companies and thousands of startups [2][10] - Chinese companies are increasingly competitive globally, with notable participation from WuXi AppTec, WuXi Biologics, and WuXi AppTec's subsidiaries, as well as several Chinese pharmaceutical firms at the main venue [2][10] - The conference will focus on "capital + strategy," highlighting the importance of deep exchanges in the industry [2][10] Group 2 - China's pharmaceutical industry is characterized by "innovation upgrade + supply chain resilience," with overseas authorizations for innovative drugs exceeding the previous year's total in the first three quarters of 2025 [3][11] - The industry is undergoing a value reconstruction, emphasizing high-quality development, innovation, and compliance, with policies promoting diverse payment methods and medical service price reforms [3][11] - The domestic pharmaceutical chain is entering a commercialization phase, with a focus on supply chain security and the transition of domestic medical devices to mid-to-high-end markets [3][11] Group 3 - The investment outlook for 2026 is optimistic, with expectations for improved global liquidity favoring the pricing of innovative assets and government policies encouraging industry innovation [4][11] - The focus on internationalization is evident, with the Chinese pharmaceutical industry gradually gaining global competitiveness, particularly in innovative drugs and medical devices [4][12] - Marginal changes in policy and supply-demand relationships are expected to improve, particularly in the CXO sector, which has seen significant adjustments [4][12] Group 4 - The report suggests a focus on the integration of medical devices and traditional Chinese medicine, as well as certain pharmaceutical companies and state-owned enterprises [4][13] - The industry faces risks related to policy changes, including adjustments in research design requirements, pricing, and reimbursement policies, which could significantly impact development expectations [6][15] - There are also risks associated with unmet expectations in research and development, as well as potential delays in approval processes due to documentation and procedural changes [17]

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.71% to close at 25,635.23 points, while the Hang Seng Technology Index decreased by 0.30% to 5,483.01 points [2] - The total market turnover for the day was HKD 224.51 billion [2] Stock Performance - Among the Hang Seng Index constituents, 22 stocks rose while 67 fell, with notable declines in Sands China Limited (-4.46%), JD Health (-3.42%), and CK Hutchison Holdings (-3.35%) [2][3] - BYD Company saw an increase of 3.74%, closing at HKD 97.10 per share, while Geely Automobile rose by 3.43% to HKD 17.50 per share [3] Geely Automobile Buyback - Geely Automobile repurchased 1.956 million shares on December 24, involving HKD 33.14 million, and has repurchased a total of 22.434 million shares in the last 30 days, totaling HKD 385 million [4] Industry Insights - The commercial rocket sector received a boost from the Shanghai Stock Exchange's new listing guidelines, which clarify the requirements for commercial rocket companies to list on the Sci-Tech Innovation Board [6][9] - The new guidelines are expected to accelerate capital operations for rocket enterprises, with a focus on long-term structural benefits rather than short-term market reactions [10] Gold Sector Performance - The gold sector faced a downturn due to a drop in gold prices, with major companies like China National Gold Group and Zijin Mining experiencing declines of 5% or more [11][12] - The domestic gold price fell, with SHFE gold closing at CNY 1,007.18 per gram, down 0.91% [12] Future Market Outlook - UBS forecasts that the upward trend in the Chinese market is likely to continue through 2026, driven by advanced manufacturing and technological self-reliance [13]

Group 1: Global Market Trends - In the context of global central banks initiating a "rate-cutting wave" and releasing ample liquidity, stock markets in multiple countries are expected to continue their upward momentum into 2025, demonstrating resilience amid macroeconomic and geopolitical shocks [1] - The MSCI global index has achieved a cumulative increase of over 20% this year, marking the third consecutive year of gains exceeding 15% [1] Group 2: Asian Market Dynamics - The AI boom has significantly boosted demand for semiconductors, with the MSCI Asia-Pacific index rising approximately 28% this year, marking the first time since 2020 that Asian stocks have outperformed US and European benchmarks in a single year [5][6] - Asia accounts for over 75% of global semiconductor manufacturing capacity, with Taiwan and South Korea leading in advanced process nodes, while China is rapidly expanding its mature process capacity [6] Group 3: Japanese and Korean Market Performance - The Nikkei 225 index has surpassed 50,000 points, with a year-to-date increase of 30%, driven primarily by technology stocks such as SoftBank Group and Advantest [7][9] - South Korea's KOSPI index has surged over 70% this year, with SK Hynix and Samsung Electronics leading the charge due to a supercycle in AI-driven memory chips [12] Group 4: European Market Insights - European stock markets have reached historical highs, supported by improved economic outlooks, lower inflation compared to the US, and significant fiscal stimulus from Germany [38][43] - The DAX index has shown resilience despite Germany's stagnant economic growth, bolstered by a massive fiscal stimulus plan aimed at infrastructure and defense spending [43][44] Group 5: North American Market Developments - Canada's TSX Composite Index has recorded a 30% increase this year, driven by strong performances in the financial, materials, and energy sectors [66][67] - Brazil and Mexico have also benefited from capital inflows due to their low valuation advantages, with both markets experiencing approximately 30% gains this year [74][75] Group 6: Future Outlook - Investors are optimistic about 2026, with expectations of continued stock market growth driven by corporate profit increases, reduced policy resistance, and AI investments [88][89] - Analysts predict that the AI-driven supercycle will lead to record capital expenditures and rapid profit expansion across various sectors, including defense and utilities [94][96]

Investment Rating - The report maintains an "Outperform" rating for several companies in the pharmaceutical sector, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with promising pipelines and performance growth in the Biopharma/Biotech sector, maintaining an "Outperform" rating for Innovent Biologics, WuXi XDC Cayman, and others [5][23]. - It highlights the performance of the A-Shares pharmaceutical sector, which underperformed the market, with the SW Pharma & Bio index falling by 0.2% while the SHCOMP rose by 1.9% [7][18]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level of 66.7% as of December 26, 2025 [13][17]. Summary by Sections 1. Continued Recommendation for Innovative Drugs and Industry Chain - The report continues to recommend innovative drugs and the associated industry chain, highlighting the high demand and potential for revaluation in the pharmaceutical sector [5][23]. - Specific companies recommended include Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical, all rated as "Outperform" [5][6]. 2. A-Shares Pharmaceutical Sector Performance - In the fourth week of December 2025, the A-Shares pharmaceutical sector underperformed the broader market, with a decline of 0.2% compared to a 1.9% increase in the SHCOMP index [7][18]. - The best-performing sub-sectors included chemical raw materials (+2.0%) and medical equipment (+0.1%), while biological products saw a slight decline of -0.1% [9][18]. 3. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index down by 1.8% and the Hang Seng Biotechnology index down by 2.3% [18]. - In contrast, the U.S. pharmaceutical sector performed similarly to the market, with the S&P Healthcare Select Sector increasing by 1.0% [18].

Market Overview - The Hong Kong stock market opened positively, with the Hang Seng Index rising by 0.43%, the National Enterprises Index increasing by 0.59%, and the Hang Seng Technology Index up by 0.88% [1][3]. Notable Stock Movements - BYD Company (01211) saw an increase of 3.53% - Geely Automobile (00175) rose by 3.31% - China Hongqiao (01378) increased by 3.28% - Li Auto (02015) gained 3.07% - In contrast, Xiaomi Group (01810) fell by 1.38%, JD Health (06618) decreased by 0.85%, and WuXi Biologics (02269) dropped by 0.31% [1][3]. Company Announcements - Longpan Technology (02465) opened 4.05% higher, announcing a change in its 2022 fundraising project plan. The annual production capacity for its new energy vehicle power and energy storage battery cathode material project was increased from 62,500 tons to 100,000 tons, a 60% increase from the original plan. The project investment is approximately 910 million RMB, with an internal rate of return of 12.59% and a payback period of 7.64 years. Completion is expected by May next year [1][3]. - MicroPort Scientific Corporation-B (02252) opened 6.7% higher after announcing that its self-developed bronchoscopic surgical robot, UniPath, received approval from the National Medical Products Administration [4]. - China Duty Free Group (01880) opened 6.78% higher, announcing that its wholly-owned subsidiary won the bid for the duty-free project at Beijing Capital International Airport, with a guaranteed operating fee of 480 million RMB for the first year and a sales commission rate of 5%. The contract is valid until February 10, 2034, for a maximum of 8 years [4]. Market Sentiment - Market sentiment was mixed, with U.S. stocks showing slight declines after a brief positive start. The S&P 500 index had reached a historical high before retreating. The U.S. dollar remained stable, and the yield on 10-year U.S. Treasuries fell to 4.13%. Gold prices continued to rise, while oil prices faced pressure [2][5]. - The mainland Chinese stock market showed a slight increase, with the Shanghai Composite Index rising by 0.1% and trading volume exceeding 2 trillion RMB [5]. - The Hong Kong market is expected to maintain a narrow trading range, fluctuating between 25,000 and 26,000 points [5].

消费行业 2025 年总结与 2026 年展望 20251228 摘要 2025 年创新药 BD 爆发，前三季度出海金额达 920 亿美元，创销板块 表现突出，港股通创销板块涨幅高达 73%。预计 2026 年中国创新药将 通过 BD 方式更深入参与全球市场，推动生态体系变化。 2025 年 A 股社服零售板块表现偏后，但免税行业在 9 月已现复苏迹象。 展望 2026 年，服务消费负贝塔效应将减弱，政策倾斜预期增强，免税 和酒店估值修复，业绩兑现窗口或将到来。 2025 年第四季度家电行业处于消化期，国家补贴边际效应降低，出口 负增长。2026 年建议关注红利、全球化、AI 端侧应用和零部件跨界四 大领域，白电龙头红利价值较高，全球化关注关税影响。 2025 年轻纺行业内需承压，外贸受关税和汇率扰动，金饰表现亮眼。 2026 年仍需自下而上挖掘高景气成长股，优选具备竞争力的外贸品种， 关注金饰、服饰、制造业和个护等细分赛道。 2025 年农业牧渔行业机会偏小波段且结构性明显，生猪养殖板块占比 最大。预计 2026 年生猪产能去化将持续推动猪价上涨，建议重仓生猪 养殖主线，关注优质资产和弹性标的。 Q&A 2 ...

《生物安全法案》复盘 --如何看待地缘政治对中国CXO企业的影响？ 行业研究 · 行业专题 医药生物 · 医疗研发外包 投资评级：优于大市（维持评级） 0755-81982723 pengsiyu@guosen.com.cn S0980521060003 证券分析师：陈曦炳 0755-81982939 chenxibing@guosen.com.cn S0980521120001 证券分析师：彭思宇 证券分析师：凌珑 021-60375401 linglong@guosen.com.cn S0980525070003 请务必阅读正文之后的免责声明及其项下所有内容 1 报告摘要 证券研究报告 | 2025年12月28日 n 靴子落地，美国《2026财年国防授权法案》夹带《生物安全法案》生效。 请务必阅读正文之后的免责声明及其项下所有内容 2 ü 《2026财年国防授权法案》夹带《生物安全法案》（主要指第851节《禁止与特定生物技术公司签订合同》）落地，标志着美国已将生物安全正式纳入国家防务与 安全战略框架统筹考量，同时彰显其在生物技术供应链自主可控的明确政策转向，本质是中美的科技竞争与产业安全博弈在生物领域的延 ...

Group 1 - The market rebound is primarily driven by enhanced logic of market winning rates both domestically and internationally [2] - Global liquidity concerns have significantly eased, particularly in the US, where the November core CPI rose by 2.6% year-on-year, the lowest since April 2021, boosting optimistic expectations for interest rate cuts [3] - Domestic market support stems from increased expectations for policy-driven liquidity easing and strengthened confidence in industrial development, with the central economic work conference setting clear policy goals for economic growth and price recovery [4] Group 2 - Technology assets are experiencing a contraction and differentiation, driven by "winning rate continuation" and "industrial explosion" logic, with telecommunications and defense industries leading the way [5] - In the cyclical sector, non-ferrous metals have performed well, benefiting from the transmission of technology industry chain prosperity and increased macro risk aversion [6] - The index is expected to show a strong upward trend, with the ChiNext index rising by 5.80% and the Shanghai Composite Index by 1.35% as of December 24 [7] Group 3 - The upcoming spring market is likely to focus on high-prosperity industries, with historical patterns indicating that strong economic conditions paired with strong industries lead to broad market gains [8] - Investment strategies should continue to focus on AI and less crowded technology sectors, global pricing resources, and consumer goods benefiting from moderate price recovery [8] - The January stock selection includes a diverse range of companies across various sectors, such as robotics, consumer goods, and advanced industries, indicating a strategic approach to capitalize on market trends [12][13]